For adult patients with type 2 diabetes, treated with diet and exercise.
When pills are no longer enough
REALIZE THE POTENTIAL WITH OZEMPIC®
Ozempic®—the only type 2 diabetes treatment with greater A1C and weight results vs Trulicity® (in SUSTAIN 7),b and study-titrated Lantus®, and as an add-on to basal insulin1,2

Ozempic® is indicated to reduce the risk of MACE for adults with T2D and established CVD1,a
Ozempic® is indicated to reduce the risk of MACE for adults with T2D and established CVD1,a

Pen shown delivers doses of
0.25 mg or 0.5 mg.
Superior results vs Trulicity® (in SUSTAIN 7)b and as an add-on to basal insulin and statistically significant results vs study-titrated Lantus®.1,2
Evaluated in a 2-year CVOT vs placebo in adults with type 2 diabetes and established CVD.

aMajor adverse CV events (MACE)=CV death, nonfatal MI, or nonfatal stroke.
bSUSTAIN 7 included 0.5 mg and 1.0 mg doses for Ozempic® and 0.75 mg and 1.5 mg doses for Trulicity®.
cWeight change was a secondary endpoint in clinical trials.
dResults apply to Ozempic® plus standard of care vs standard of care alone in SUSTAIN 6 trial for patients with T2D and established CVD.
T2D=type 2 diabetes; CVD=cardiovascular disease; CVOT=cardiovascular outcomes trial; CV=cardiovascular; GLP-1 RA=glucagon-like peptide-1 receptor agonist; MI=myocardial infarction.
Ozempic® is indicated to reduce the risk of MACE for adults with T2D and established CVD1,a

Pen shown delivers doses of 0.25 mg or 0.5 mg.
Ozempic®—the only type 2 diabetes treatment with greater A1C and weight results vs Trulicity® (in SUSTAIN 7),b and study-titrated Lantus®, and as an add-on to basal insulin1,2

aMajor adverse CV events (MACE)=CV death, nonfatal MI, or nonfatal stroke
bWeight change as a secondary endpoint in clinical trials.
cResults apply to Ozempic(r) plus standard of care vs standard of care alone in SUSTAIN 6 trial
T2D=type 2 diabetes; CVD=cardiovascular disease; CVOT=cardiovascular outcomes trial; CV=cardiovascular; MI=myocardial infarction.
aMajor adverse CV events (MACE)=CV death, nonfatal MI, or nonfatal stroke.
bSUSTAIN 7 included 0.5 mg and 1.0 mg doses for Ozempic® and 0.75 mg and 1.5 mg doses for Trulicity®.
cWeight change was a secondary endpoint in clinical trials.
dResults apply to Ozempic® plus standard of care vs standard of care alone in SUSTAIN 6 trial for patients with T2D and established CVD.
T2D=type 2 diabetes; CVD=cardiovascular disease; CVOT=cardiovascular outcomes trial; CV=cardiovascular; GLP-1 RA=glucagon-like peptide-1 receptor agonist; MI=myocardial infarction.
Resources for starting patients
Whether you’re starting your patients on Ozempic® in person or via telehealth, use these quick links to find all the resources you need.


EXPLORE EXPERT INSIGHTS
Ozempic® vs Trulicity®
Learn about the results of a head-to-head trial of 2 once-weekly GLP-1 RA therapies from one of the primary investigators.